Most patients who come to me for hair restoration consultations have already tried something. Minoxidil. Biotin supplements. A shampoo from an Instagram ad. Maybe finasteride, if they've seen a physician. They come in skeptical — and honestly, after the noise in the hair loss space, that skepticism is earned.

So when I recommend FoLix laser hair restoration, I don't ask patients to take it on faith. I explain exactly what it does at the cellular level, why the evidence supports it, and what realistic outcomes look like. That's what this article is: the full science, without the marketing language.

First: Understanding Why Hair Is Lost

To understand how FoLix works, you first have to understand why hair miniaturizes and stops growing in the first place.

In androgenetic alopecia — the most common form of hair loss in both men and women — the primary driver is dihydrotestosterone (DHT), a metabolite of testosterone produced by the enzyme 5-alpha reductase. DHT binds to androgen receptors in genetically susceptible hair follicles, triggering a progressive shortening of the anagen (active growth) phase and a lengthening of the telogen (resting) phase. Over successive cycles, the follicle miniaturizes — producing progressively finer, shorter, and lighter hairs — until it eventually stops producing a visible shaft entirely.

The critical clinical point: this process is gradual, and follicles that have miniaturized but not yet permanently closed can be reactivated. Once a follicle is completely gone — once the dermal papilla has been irreversibly lost — no treatment can regenerate it. This is why early intervention produces the best outcomes. Not because we want to sell more treatment, but because the biology is unforgiving about timing.

What Is Photobiomodulation?

Photobiomodulation (PBM) — also called low-level laser therapy (LLLT) — is the application of specific wavelengths of light to biological tissue to stimulate cellular activity. The term "low-level" distinguishes it from ablative lasers that destroy tissue. PBM doesn't cut, burn, or remove anything. It stimulates.

The concept sounds simple, but the underlying mechanism is genuinely sophisticated. When photons at the right wavelengths strike living tissue, they are absorbed by specific chromophores — light-absorbing molecules — within cells. The primary chromophore relevant to FoLix therapy is cytochrome c oxidase, a protein complex that sits in the inner mitochondrial membrane and plays a central role in the electron transport chain — the cellular process by which ATP (adenosine triphosphate) is synthesized.

ATP is the energy currency of the cell. When cytochrome c oxidase absorbs photons in the red-to-near-infrared range (approximately 630–850 nm), it undergoes a conformational change that increases its enzymatic activity, enhancing electron transport and dramatically increasing ATP production in the treated tissue.

What This Means for a Hair Follicle

A miniaturizing hair follicle is, in essence, an energy-deficient follicle. The cellular machinery needed to maintain the anagen phase — the dermal papilla cells, the matrix keratinocytes, the melanocytes producing pigment — all require substantial ATP to function. When DHT disrupts follicular signaling, the result is a progressive reduction in the metabolic activity of these cells.

Photobiomodulation addresses this directly. By increasing mitochondrial ATP production in follicular tissue, FoLix essentially provides miniaturizing follicles with the cellular energy needed to resist the miniaturization process and re-enter the anagen phase. Several additional mechanisms have been identified in the research literature:

• Increased proliferation of dermal papilla cells — the specialized cells at the base of the follicle that regulate the hair cycle. Published in vitro studies have shown significant increases in dermal papilla cell proliferation following LLLT exposure.
• Upregulation of growth factors — including vascular endothelial growth factor (VEGF), which increases blood flow to the follicle and improves nutrient delivery, and hepatocyte growth factor (HGF), which promotes hair follicle cell survival.
• Reduction of oxidative stress — PBM has been shown to reduce reactive oxygen species (ROS) within follicular tissue, reducing cellular damage from oxidative stress — a contributor to follicular miniaturization that is independent of DHT.
• Wnt/β-catenin pathway activation — one of the primary molecular pathways governing hair follicle cycling. LLLT has been shown to upregulate Wnt signaling, which promotes the shift from telogen to anagen and encourages follicular stem cell activation.

The Hair Cycle: Why Timing Matters

Hair follicles cycle through three phases: anagen (active growth, typically 2–7 years), catagen (transitional involution, 2–3 weeks), and telogen (resting, 3–4 months). In a healthy scalp, approximately 85–90% of follicles are in anagen at any given time.

In androgenetic alopecia, this ratio inverts progressively. The anagen phase shortens. More follicles spend more time in telogen. Eventually, the follicle produces no visible hair at all.

FoLix therapy works by promoting the shift from telogen back into anagen — and by extending the duration of the anagen phase once a follicle re-enters it. This is why the clinical timeline looks the way it does: reduced shedding typically appears first (at 6–8 weeks), as the abnormal telogen shift is interrupted, followed by visible density improvement (at 12–16 weeks) as miniaturized follicles re-enter anagen and begin producing thicker shafts.

The Clinical Evidence

LLLT for hair loss is one of the better-studied non-pharmacological interventions in dermatology. A few landmark findings worth knowing:

• A 2013 randomized controlled trial published in the American Journal of Clinical Dermatology found a 39% increase in hair count in men with androgenetic alopecia after 26 weeks of LLLT treatment compared to a sham device control.
• A 2014 double-blind, sham-device-controlled trial in women found statistically significant increases in hair count and hair thickness following 16 weeks of LLLT.
• A 2017 meta-analysis of seven randomized controlled trials concluded that LLLT was both safe and effective for androgenetic alopecia in both men and women, with no significant adverse effects reported across trials.
• Multiple studies have demonstrated that LLLT can be safely combined with minoxidil or finasteride, with some data suggesting additive or synergistic effects.

This is not a fringe treatment. It is FDA-cleared, peer-reviewed, and reproducible. The mechanism is understood. The clinical outcomes are measured.

What FoLix Delivers — and What It Doesn't

I am going to be direct, because I think patients deserve honesty about what any treatment can and cannot do.

FoLix laser therapy will not regrow hair in areas where follicles have been permanently lost. If a patient presents with completely slick, smooth scalp in an area — no vellus hairs visible, no follicular openings under dermoscopy — there is no follicle left to stimulate. No treatment can reverse that. A transplant can move follicles from elsewhere on the scalp, but that is a different intervention entirely.

What FoLix can do, with consistency, is slow further miniaturization, stabilize active hair loss, and produce measurable density improvement in areas where follicles are miniaturized but still present. For patients in the early-to-mid stages of androgenetic alopecia — Norwood I–IV in men, Ludwig I–II in women — the potential benefit is significant.

The earlier treatment begins, the more follicles are available to respond. This is not a sales pitch. It is biology.

What a FoLix Treatment Looks Like at DRM

Before any treatment is scheduled, I conduct a full clinical assessment: review of medical history, evaluation of any contributing factors beyond androgenetic alopecia (thyroid function, iron levels, nutritional deficiencies, medications), and dermoscopic examination of the scalp to stage the pattern of loss and identify areas with remaining follicular reserve.

The treatment itself is straightforward: comfortable, painless, and completed in-office. The device delivers calibrated photobiomodulation energy to the scalp. Patients describe it as a gentle warmth. There is no downtime, no recovery, and no restriction on normal activity afterward.

Treatment protocols are individualized based on the assessment findings. Maintenance sessions are required to sustain results — the biology of the hair cycle means that the cellular stimulus needs to be maintained for ongoing benefit.